Nitin Jain, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of inotuzumab ozogamicin, an antibody-drug conjugate, for relapsed/refractory Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (Ph+ ALL) or chronic myeloid leukemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).